Press coverage about Arcturus Therapeutics (NASDAQ:ARCT) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arcturus Therapeutics earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 44.7501472906596 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

A number of analysts recently issued reports on ARCT shares. Ladenburg Thalmann Financial Services started coverage on Arcturus Therapeutics in a research report on Wednesday, November 29th. They set a “buy” rating for the company. Chardan Capital began coverage on Arcturus Therapeutics in a research report on Monday, January 22nd. They set a “buy” rating and a $12.00 price objective for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $3.08.

Shares of Arcturus Therapeutics (NASDAQ:ARCT) traded down $0.04 during trading hours on Thursday, hitting $5.54. The company’s stock had a trading volume of 44,281 shares, compared to its average volume of 82,774. Arcturus Therapeutics has a 12 month low of $4.78 and a 12 month high of $15.19. The firm has a market capitalization of $59.77, a PE ratio of -1.40 and a beta of 1.44.

COPYRIGHT VIOLATION WARNING: “Arcturus Therapeutics (ARCT) Getting Somewhat Positive Press Coverage, Report Finds” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms.

Insider Buying and Selling by Quarter for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with's FREE daily email newsletter.